Lorglumide

Lorglumide
Clinical data

ATC code	none
Identifiers
IUPAC name N²-(3,4-Dichlorobenzoyl-N,N-dipentyl-α-glutamine
Synonyms	4-[(3,4-dichlorobenzoyl)amino]-5-(dipentylamino)-5-oxopentanoic acid
CAS Number	97964-56-2^Y
PubChem CID	3960
IUPHAR/BPS	891
ChemSpider	3823^N
UNII	LAD1UQ73BE
ChEBI	CHEBI:88305^N
ChEMBL	CHEMBL24938^N
Chemical and physical data
Formula	C₂₂H₃₂Cl₂N₂O₄
Molar mass	459.406 g/mol
3D model (Jmol)	Interactive image
SMILES CCCCCN(CCCCC)C(=O)C(CCC(=O)O)NC(=O)C1=CC(=C(C=C1)Cl)Cl
InChI InChI=1S/C22H32Cl2N2O4/c1-3-5-7-13-26(14-8-6-4-2)22(30)19(11-12-20(27)28)25-21(29)16-9-10-17(23)18(24)15-16/h9-10,15,19H,3-8,11-14H2,1-2H3,(H,25,29)(H,27,28)^N Key:IEKOTSCYBBDIJC-UHFFFAOYSA-N^N
^NY (what is this?)

Lorglumide (CR-1409) is a drug which inhibits gastrointestinal motility and reduces gastric secretions, acting as a cholecystokinin antagonist, with fairly high selectivity for the CCK_A subtype. It has been suggested as a potential treatment for a variety of gastrointestinal problems including stomach ulcers, irritable bowel syndrome, dyspepsia, constipation and pancreatitis, as well as some forms of cancer, but animal and human testing has produced inconsistent results and no clear therapeutic role has been established, although it is widely used in scientific research.

...
Wikipedia